Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea.
- Author:
Dae Hyoung LEE
1
;
Nak Gyun CHUNG
;
Bin CHO
;
Hack Ki KIM
;
Hyoung Jin KANG
;
Hee Young SHIN
;
Hyo Seop AHN
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Hoon KOOK
;
Tai Ju HWANG
;
Ho Joon IM
;
Jong Jin SEO
;
Hyeon Jin PARK
Author Information
- Publication Type:Original Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
- Keywords: Leukemia, Myeloid, Acute; Enocitabine; Childhood
- MeSH: Adolescent; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Child; Child, Preschool; Combined Modality Therapy; Cytarabine/*analogs & derivatives/*therapeutic use; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin/*therapeutic use; Infant; Infant, Newborn; Leukemia, Myeloid, Acute/*drug therapy/mortality; Male; Republic of Korea; Retrospective Studies; Survival Analysis; Thioguanine/*therapeutic use; Young Adult
- From:Journal of Korean Medical Science 2010;25(1):9-15
- CountryRepublic of Korea
- Language:English
- Abstract: We investigated the outcome of idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosyl cytosine (BHAC)-based chemotherapy (BHAC group, n=149) compared to idarubicin plus cytarabine-based chemotherapy (cytarabine group, n=191) for childhood acute myeloid leukemia (AML). Between January 1996 and December 2005, 340 children with AML from 5 university hospitals in Korea received the BHAC-based or cytarabine-based chemotherapy, with or without hematopoietic stem cell transplantation. After induction therapy, 264 (77.6%) of 340 children achieved a complete remission (CR) and 43 (12%) achieved a partial remission (PR). The CR rate in the BHAC group was higher than in the cytarabine group (85.2% vs. 71.7%, P=0.004). However, the overall response rate (CR+PR) was not different between the two groups (93.3% vs. 87.9%, P=0.139). The 5-yr estimates of overall survival (OS) of children in the two groups were similar (54.9% for the BHAC group vs. 52.4% for the cytarabine group, P=0.281). Although the results were analyzed according to the treatment type and cytogenetic risk, the OS showed no significant difference between the BHAC group and the cytarabine group. In the present study, the clinical outcomes of the BHAC-based chemotherapy, consisting of BHAC, idarubicin, and 6-TG, are comparable to that of the cytarabine-based chemotherapy for childhood AML.
